QTRX•November 16, 2026 at 6:30 PM UTCHealth Care Equipment & Services

Quanterix Expands Alzheimer's Test Access in NJ via Exclusive Lab Deal, but Scale and Competitive Hurdles Persist

Read source article

What happened

Quanterix announced an exclusive distribution agreement with Brooklyn-based Sherman Abrams Laboratory to offer its LucentAD Complete blood tests in New Jersey and surrounding areas. The partnership aims to increase patient access to Quanterix's multi-marker Alzheimer's test, which leverages the Simoa platform and screens for multiple biomarkers. However, the deal is with a single regional lab, and Quanterix faces tough competition from FDA-cleared tests from Fujirebio, Roche, and Quest, which have broader distribution networks. The company continues to burn cash, with 9M25 operating cash outflow of $60.8 million, and must still integrate the Akoya acquisition and reach cash-flow breakeven in 2026 as previously guided. While this news is a positive incremental step in commercializing LucentAD, it does not materially alter the investment thesis of a high-potential but still loss-making company.

Implication

Investors should view this agreement as a small tactical win rather than a strategic breakthrough. It demonstrates Quanterix's ability to secure regional distribution partnerships, but the impact will depend on test volumes and reimbursement uptake in that region. Competition from larger players with FDA-cleared tests and established logistics remains a significant barrier to scaling LucentAD nationally. The company's path to cash-flow breakeven still hinges on cost reductions and broader revenue growth, not on a single distribution deal. Therefore, investors should continue to monitor quarterly cash burn, LucentAD revenue growth, and progress on Akoya integration before adding exposure.

Thesis delta

The core thesis remains intact: Quanterix holds differentiated technology but is structurally loss-making and faces intense competition. This exclusive distribution deal is a small positive that supports the Alzheimer's diagnostics commercial story but does not address the larger challenges of scaling against larger rivals or achieving profitability. No change to the WAIT rating or valuation range is warranted at this time.

Confidence

Medium